Single abnormal genetic profile-dedicated PCR amplification

In order to characterize cancers with single specific abnormalities, Ipsogen uses PCR (Polymerase Chain Reaction) that combines both ease of use and high sensitivity.  This enzyme-based amplification technology allows, starting from a low abundance complex sample, the production of millions of copies of the target sequence in just a few hours.

Ipsogen uses advanced versions of this technology, called quantitative PCR (RQ-PCR), to study leukemia. A copy of the transcriptome (the full set of genes expressed by a cell at a given time) undergoes specific amplification of target genes, allowing the accurate measurement of their respective expression levels.

Complex profile molecular signature-dedicated DNA microarrays

In order to establish the molecular diagnosis of heterogeneous diseases like breast cancer, resulting from large numbers of genetic abnormalities, Ipsogen uses DNA biochips that allow the simultaneous measurement of the expression levels of several thousands of genes and that are compatible with small specimens such as fine needle biopsies.

Among biochip manufacturers, Ipsogen has chosen Affymetrix, the market world leader and reference platform of main European and American institutes.

Ipsogen has developed proprietary algorithm-based tools for data mining and result analysis.

Since its start, Ipsogen has shown an impressive know-how in bioinformatics that has allowed the development of proprietary algorithms dedicated to mining expression profiles.
After completion of the tumor pan-genomic profiling, data are sent electronically and analyzed by Ipsogen's experts. Results are returned through the web to pathology labs or to hospitals.